Key Takeaways
- Price bottom confirmed, margin recovery ahead: Management declared chemical prices have bottomed at near all-time lows and are "bound to bounce up," while all high-cost inventory has been cleared, setting the stage for profit growth from current low-price stock.
- Volume growth offsetting price erosion: Despite a 10–12% average price decline, the company delivered decent double-digit volume growth in the first nine months, with similar trends continuing in Q4.
- Focused Maharatna strategy is working: The top dozen Focused Maharatna products grew ~15%, while tail products were deliberately phased out, compressing overall revenue but improving portfolio quality and margin profile.[12-13]
- Shinwa becomes the flagship product: The Nissan-partnered insecticide reached ~₹150 cr in gross sales this year, up from ~₹70 cr last year, making it the largest product in the portfolio.
- What to watch next quarter: Whether Chinese price increases of 10–20% materialize, the pace of margin recovery from Q1, and the market reception for six new kharif-season brands.
Price Cycle & Margin Recovery
- The collapse and the floor: Post-COVID, chemical prices spiked on huge demand, then reversed sharply after Diwali last year, badly damaging Q4 performance. Management now says prices have stabilized at very low levels and are near all-time lows, making this "a good buying time."
- Inventory reset complete: All high-priced inventory that caused a loss in Q4 last year has been cleared. Current inventory was purchased at low prices over the last 3–4 months and will be more profitable going forward.
- Volume doing the work: Prices were continuously under pressure with a 10–12% average impact, but the company achieved decent double-digit volume growth in the nine-month period, with similar volume growth happening in Q4 around key products.
- Margin walk: Gross margins are "a little lower" currently, and the company is working on improvement through product mix changes. Management expects a step-by-step margin increase, with a decent rise in the next fiscal year, visible from Q1 itself.
- Past investment drag fading: Before COVID, heavy investments in R&D and manufacturing expansions were subsidized by brand and B2B income. The company is now debt-free, has funds, is growing the top line, and expects bottom-line growth to follow.
Rajesh Aggarwal: "There is no guarantee that everything has bottomed out, but it looks that they are very much near the bottom because they are near all-time low. So, this is a good buying time."
Product Portfolio & Strategy
- Focused Maharatna as the engine: The strategy of dividing the range into Maharatna and Focused Maharatna has worked well. Focused Maharatna products grew about 15%, while overall growth was flat because tail products declined sharply, a deliberate move to phase out low-margin products.[12-13]
- Product rationalization underway: The company is working to remove a few dozen products from the range. More than half have already been finished, and 75–80% of the balance will be completed by year-end.
- Maharatna contribution target: Management aims to maintain 60%+ contribution from Maharatnas next year, with a vision to reach 65% and eventually 70% over 2–3 years.
- Herbicide build-out: The company is focusing on herbicides and has bagged registrations across all leading crops. Hachiman (Japanese mixture) is doing very well in soybean; Torry launched last year for corn with great success; Super Torry and Taurus are launching for the entire corn/maize spectrum.
- Insecticide strength: Beyond Shinwa, Mission (SC and GR formulations) achieved ~₹80 cr in gross sales in half a year. Hercules continues increasing sales year-by-year, and Dominant (launched three years ago) is set to increase this year.
- Fungicide repositioning: Led by Pulsor, the company re-introduced Izuki and will concentrate around Izuki and Sofia with an improved strategy.
- Biological segment entry: A few patents have been filed in the biological segment, with new mixtures and next-generation products developed. Nirog, a new fungicide for sugarcane, is in test launch stage. Management wants to grow biological products "in a big way" but will go subtle on acceptance-building.
Rajesh Aggarwal: "The good part is that Focused Maharatna has grown over 50% in the previous year. So that was the reason we wanted to do that and very successfully, we are able to deliver that to the market because we need these products our engines and very well accepted across the country, I can say."
Manufacturing & Backward Integration
- Chopanki expansion: Fully operational.
- Dahej plant: Partially started, with some approvals still awaited. Management is confident of being fully operational this quarter. Dahej will provide raw material security, with most new herbicides and 1–2 insecticides coming from this plant.
- Sotanala plant: Final plans are near freezing. Once the ground-breaking ceremony is done, an 18-month program will begin, and execution is expected to be quite fast.
- Reactor scale: The company currently has around 150 reactors, with 150 more being added, totaling roughly 300 reactors for manufacturing technicals.
- Backward integration thesis: The expanded manufacturing base is designed to provide raw material security and support the growing portfolio of in-house technicals, reducing dependence on external sourcing.
Distribution & Digital Initiatives
- Distribution strength: The distributor network has been working with the company for 2–3 generations and is deeply attached. Response from retailers and farmers remains good. The current dealer/distributor count is approximately 8,500, with regular additions as an ongoing exercise.
- IL360 digitization program: A last-mile connectivity initiative connecting retailers and farmers via Crop Advisers (CAs), who operate on a third-party model and are not covered by SAP ERP. IL360 will enable faster two-way communication for new launches, schemes, products, and solutions.
- Salesforce CRM: The company has tied up with Salesforce for CRM to cover all retailers and focus on the growth of key retailers.
- Seasonal selling discipline: The company sells near season only and does not do aggressive advance placements. This explains the lower Q3 performance, and Q4 is also expected to be an affected quarter.
Market Environment & Demand
- Global headwinds: Crisis in the USA, Latin America, and Europe due to drought, with distributors and companies holding high-priced inventory causing trouble. CIS, African countries, and the Middle East face currency trouble due to dollar unavailability and currency decline. Asia is relatively better due to good rainfall during the kharif season.
- India climatic impact: Good climatic conditions in the kharif season, but the rabi season has seen more drought-type conditions, resulting in a decline in sales/demand for agrochemicals. Crop holidays for paddy in Karnataka, Telangana, and parts of Andhra, plus a poor chilli crop, added pressure.
- Seasonal business pattern: 60–65% of business occurs in the kharif season (first half), with approximately 40% in the rabi season (second half).
- All segments expected to grow: B2C, B2B, and International Business are all bound to grow reasonably. The domestic brand image helps B2B and international sales, and as the global situation settles, the company expects to bag more registrations in international markets.
Rajesh Aggarwal: "But today, if you look at today's scenario, we can say that the price has bottomed, and the prices have stabilized at a level which is almost a very low level, and they are bound to bounce up from here."
Innovation & New Launches
- Six new brands for kharif: About half a dozen products are lined up across herbicide, insecticide, and fungicide segments, with manufacturing facilities ready.
- New technologies from Nissan: Nissan remains a key partner, with new technologies coming through the relationship.
- Isoxazole JV product: Still under data generation in Japan and India. The application is expected to be filed by the end of this year, with a launch approximately two years down the line.
- OAT product: Expected to launch from the OAT-IIL JV.
- Biological launches: Certain biological products will be launched shortly.
- Launch cadence: The company targets half a dozen launches on average every year. [16-17]
Rajesh Aggarwal: "My vision is that I have to bring new solutions and I have to bring new IP protected solutions to the farmer, so that the retailer also enjoys, the dealer network also enjoys and the farmer or a consumer also gets the solution."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej plant fully operational | All approvals received and plant running | This quarter (Q4 FY24) |
| Sotanala plant start | Ground-breaking, then 18-month build program | Plans near freezing; start imminent |
| Product rationalization completion | 75–80% of remaining tail products removed | By year-end |
| Maharatna contribution | Reach 65% of sales from Maharatnas | Next year |
| Maharatna contribution | Reach 70% of sales from Maharatnas | Over 2–3 years |
| Margin improvement | Decent increase, visible step-by-step | From Q1 next fiscal |
| Isoxazole JV product | Application filed | End of this year |
| Isoxazole JV product | Commercial launch | ~2 years from filing |
| New kharif launches | Half a dozen new brands across herbicide, insecticide, fungicide | Kharif season |
| Biological product launches | Certain biological products launched | Shortly |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Net revenue | ₹358 crore, marginally up from ₹356.5 crore in Q3 FY23 |
| 9M FY24 net revenue | ₹1,693.8 crore, up 13% YoY from ₹1,499.4 crore |
| EBITDA (excl. other income) | ₹26 crore, up 11.84% YoY from ₹23.26 crore |
| 9M FY24 EBITDA | ₹153.59 crore, up 2.28% YoY from ₹150.16 crore |
| Profit after tax | ₹12.31 crore, up 31.41% YoY from ₹9.37 crore |
| 9M FY24 profit after tax | ₹94.6 crore, up 2.26% YoY from ₹92.5 crore |
| Maharatna and Focused Maharatna revenue growth | ~14% YoY in the segment |
| Maharatna share of total net revenue (9M FY24) | 62%, up from 54% in 9M FY23 |
| Focused Maharatna growth | ~15% (per management confirmation) |
| Average price impact | 10% to 12% decline, offset by decent double-digit volume growth |
| Insecticides category share | 52% of revenue, up from 45% in Q3 FY23 |
| Herbicides category share | 35% of revenue, down from 43% in Q3 FY23 |
| Fungicides category share | 9% of revenue, up from 8% in Q3 FY23 |
| B2C segment share | ~78% of revenue, flat YoY |
| B2B segment share | 16% of revenue, down from 18% in Q3 FY23 |
| Exports segment share | 6% of revenue, up from 4% in Q3 FY23 |
| Distributor network | ~8,500 running distributors |
| Shinwa gross sales (cumulative) | ~₹150 crore, up from ~₹70 crore in the comparable prior-year period |
| Mission gross sales (half year) | ~₹80 crore |
| Biological segment annual gross sales | ~₹40 crore, stagnant |
| R&D spend (annual run-rate) | ₹12 crore to ₹15 crore |